Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Contineum Therapeutics, Inc. - Common stock (CTNM)
Company Research
Source: Business Wire
SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11th at 2:20 p.m. ET.An audio webcast of the fireside chat can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available.About Contineum TherapeuticsContineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed programs with multiple drug candidates now in clinical trials. PIPE-791 is an LPA1 receptor antagonist in clinical development for idiopathic pulmonary fibrosis and ch
Show less
Read more
Impact Snapshot
Event Time:
CTNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTNM alerts
High impacting Contineum Therapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
CTNM
News
- Contineum Therapeutics (CTNM) had its price target raised by Robert W. Baird from $14.00 to $20.00. They now have an "outperform" rating on the stock.MarketBeat
- Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones [Yahoo! Finance]Yahoo! Finance
- Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development MilestonesBusiness Wire
- Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus [Yahoo! Finance]Yahoo! Finance
- Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
CTNM
Earnings
- 3/5/26 - Beat
CTNM
Sec Filings
- 3/5/26 - Form S-8
- 3/5/26 - Form 424B5
- 3/5/26 - Form 10-K
- CTNM's page on the SEC website